Muss H.B., Richards F., Jackson D.V.
è ñîàâò. Vincristine, doxorubicin and
cyclophosphamide versus low dose intravenous cyclophosphamide, methotrexate and
5 fluorouracil in advanced breast cancer // Cancer. — 1982. — V. 50. — P. 2269 2274.
Myers W.P.L., Buckman K.
Studies on the pathogenesis of cancer hypercalcemia //
Trans. Am, Clin. Climatol Ass. — 1976. — V. 88. — P. 177 190.
Nair N., Mahadeo D.S., Patel R.
Does renal damage occur after the administration
of 32P for palliation of pain from skeletal metastases? // Nucl. Med. Commun. — 1998. —
V. 19(7). — P. 689 693.
Nair N.
Relative efficacy of 32P and 89Sr in palliation in skeletal metastases // J.
Nucl. Med. — V. 40(2). — P. 256 261.
Nemoto T., Jatel J., Ronser D., Dao Th. L.
Tamoxifen (Nolvadex) versus adrenalec
tomy in metastatic breast cancer // Cancer. — 1984. — V. 53. — P.1333 1335.
Neri B., Gemelli M.T., Sambataro S.,
è ñîàâò. Subjective and metabolic effects of
clodronate in patients with advanced breast cancer and symptomatic bone metastases //
Anticancer Drugs. — 1992. — V. 3. — P. 87 90.
Nguyen+Pamart M., Bonneterre J., Hecquet B.
Urinary excretion of deoxypyridino
line in patients with breast cancer // Anticancer Res. — 1995. — V. 15(4). — P. 1601 1603.
Nicolini A., Ferrari P., Sagripanti A., Carpi A.
The role of tumour markers in pre
dicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy // Br.
J. Cancer. — 1999. — V. 79(9 10). — P. 1443 1447.
Niell H.B., Neely C.L.
è ñîàâò. The postabsorbtive hydroxyproline in the long term
evalution of patients with breast cancer // Cancer. — 1983. — V. 52(8). — P.1442 1447.
Nielsen O.S., Bentzen S.M., Sandberg E., Gadeberg C.C., Timothy A.R.
Randomized
trial of single dose versus fractionated palliative radiotherapy of bone metastases //
Radiother. Oncol. — 1998. — V. 47(3). — P. 233 240.
Noguchi S., Koyama H., Nomura Y.,
è ñîàâò. Late phase II study of TAT 59 (new
antiestrogen) in advanced or recurrent breast cancer patient: a double blind comparative
study with tamoxifen citrate // Breast Cancer Res Treat. — 1998. — V.50. — P. 307.
Nomura Y., Kondo H., Yamagata J.
è ñîàâò. Evaluation of liver and bone scanning
in patients with early breast cancer, based on results obtained frommore advanced patients
// Eur. J. Cancer. — 1978. — V. 14 — P. 1129 1136.
Nordman E., Marjamaki H., Tannila O.
The reliability of Tc99m pyrophospate
scintigraphy in the diagnosis of bone metastases // Ann. Clin. Res. — 1977. — V. 9. — P.
31 34.
O`Brien D.P., Horgan P.G., Gough D.B.
CA 15 3: a reliable indicatos of metastatic
bone disease in breast cancer patients // Ann. R. Coll. Surg. Engl. — 1992. — V. 74 (1). —
P. 9 11.
O'Hanlon D.M., Kerin M.J., Kent P.J., Skehill R., Maher D., Grimes H., Given H.F.
A prospective evaluation of CA15 3 in stage I carcinoma of the breast // J. Am. Coll. Surg.
— 1995. — V. 180(2). — P. 210 212.
Ohara K., Yoshida A., Sugahara S.
Analisis of patients surviving for six months after
irradiation of bone metastasis // Gan. No. Rinsho. — 1989. — V. 35(14). — P.1655 1659.
Ohishi K., Fujita N., Morinaga Y., Tsuruo T.
H 31 human breast cancer cells stimu
late type I collagenase production in osteoblast like cells and induce bone resorption //
Clin. Exp. Metastasis. — 1995. — V. 13(4). — P. 287 295.
O
,
Rourke N.P., McCloskey E.V., Vasikaran S.
è ñîàâò. Effective treatment of malig
nant hypercalcaemia with a single intravenous infusion of clodronate // Br. J. Cancer. —
1993. — V. 67. — P. 560 563.
240
Êîñòíûå ìåòàñòàçû ðàêà ìîëî÷íîé æåëåçû
